
Member-based investor group funding early-stage companies through monthly review and a chapter roadshow

San Francisco biotechnology investment partnership using in-house clinical trial analytics

In San Francisco, Logos Capital invests in biotechnology companies, combining scientific and financial expertise with in-house clinical trial analytics. The firm says its mandate is to deliver strong long-term returns for investors while financing innovation that could advance the standard of care for patients.
Each investment is underwritten with an analysis of clinical trial data, and the firm tracks the events that matter to each company, such as milestones and changes in risk. Its process treats drug development as more than scientific research, weighing clinical, regulatory and commercial factors alongside the science.
The team assesses an asset from its preclinical data through to its commercial potential, in order to estimate its intrinsic value. The firm says it screens public and private companies in its sector for those that could offer clear advances on current treatment, and that it prices its positions against that assessment.
Risk management is built into each decision through several layers, with the aim of keeping the investment logic aligned with the interests of the people who fund the firm. The team combines chemistry, engineering, biology, data science, medical, scientific and statistical disciplines, and the firm describes its approach as rooted in technical diligence and continuous improvement.
The firm's website names companies it follows, and the firm says it tracks both private and public companies across the sector. They include Aligos Therapeutics, which develops treatments for liver diseases and viral infections; ALX Oncology, which develops immuno-oncology therapies that block a checkpoint used by cancer cells; Annexon Biosciences, which develops inhibitors for complement-mediated diseases; Athira Pharma, which develops regenerative therapies for neurological disease; and Avidity Biosciences, a privately held company working on antibody oligonucleotide conjugates.
Logos Capital is a biotechnology-focused investment partnership based in San Francisco. It pairs scientific and financial skills with clinical trial analytics done in-house. The name comes from the Greek word for logic and discourse.
Biotechnology companies working on new therapies. Portfolio companies named on its site include Aligos Therapeutics, ALX Oncology, Annexon Biosciences, Athira Pharma and Avidity Biosciences.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Logos Capital.
Similar listings buyers compare against this one.

Member-based investor group funding early-stage companies through monthly review and a chapter roadshow

Startup accelerator and early-stage investor running intensive batches for new technology founders

Venture capital firm partnering with founders from first idea through to public listing

Global venture capital firm and accelerator backing early-stage technology founders, formerly called 500 Startups

Decentralised bandwidth network on which developers build and users run censorship-resistant VPN applications

Venture firm backing founders using AI and automation for health and sustainability

Venture and growth investor building communications and technology companies with entrepreneurs

Direct lender and credit manager financing private-equity-backed middle market companies
Everything here links back to the same verified catalogue. Pick your next stop.